Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has completed the second tranche of its previously announced private placement, raising an additional $2.5 million to fund its ongoing clinical development. The company issued 6,250,000 units at a price of $0.40 per unit, with each unit consisting of one common share and one common share purchase warrant. The warrants allow holders to purchase an additional common share at $0.50 for a period of three years.
With this closing, Ocumetics has raised aggregate gross proceeds of $2,948,130 under the offering. The company intends to use the net proceeds to fund its first-in-human clinical trials, continue research and development, and for general working capital. The total offering is for up to 8,000,000 units, with the remaining tranches expected to close subsequently.
In connection with the offering, Ocumetics paid Ventum Financial Corp. cash commissions of $200,000 and issued 500,000 warrants as a finder's fee. The warrants are subject to an acceleration clause, allowing the company to shorten their expiry if the common shares trade at or above $0.75 for 30 consecutive trading days.
This funding is critical for Ocumetics as it advances its innovative intraocular lens technology, which aims to eliminate the need for corrective lenses. The lens is designed to fit within the natural lens compartment of the eye and utilize the eye's natural muscle activity to shift focus, potentially providing clear vision at all distances without glasses or contact lenses.
The company's progress is noteworthy given the potential impact on the ophthalmology field. If successful, this technology could transform vision correction, offering a permanent solution for millions of people worldwide. The successful completion of this financing round demonstrates investor confidence in the company's approach and its ability to execute its clinical development plan.
Ocumetics is currently in the first-in-human early feasibility study phase, and the additional capital will help ensure the continuation of these trials. The company's focus on research and development is aimed at bringing this game-changing technology to market, which could significantly improve the quality of life for patients.
The securities issued in this tranche are subject to a four-month and one-day hold period from the date of issuance, except for warrants issued to finders, which are non-transferable. The offering is subject to final approval from the TSX Venture Exchange.
This financing represents a significant milestone for Ocumetics as it progresses toward its goal of revolutionizing vision correction. With the additional funds, the company is well-positioned to advance its clinical trials and continue its innovative research.
